<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02477878</url>
  </required_header>
  <id_info>
    <org_study_id>BP-008</org_study_id>
    <nct_id>NCT02477878</nct_id>
  </id_info>
  <brief_title>Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant</brief_title>
  <official_title>A Phase I Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bellicum Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bellicum Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I study of BPX-501 T cell infusion in adults with recurrent or minimal residual&#xD;
      disease (MRD) hematologic malignancies post-allogeneic transplant. The treatment consists of&#xD;
      increasing doses of BPX-501 T cell infusions to achieve a clinical response. Rimiducid will&#xD;
      be investigated for the treatment of aGvHD after BPX-501 T cell infusion to determine a dose&#xD;
      that can mitigate GvHD and preserve the graft versus leukemia effect.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Unmanipulated donor lymphocyte infusion (DLI) is used after stem cell transplantation to&#xD;
      treat and prevent relapse, to prevent infections and to establish full donor chimerism. The&#xD;
      addition of mature T cells which exhibit a broad repertoire of T cell immunity against viral&#xD;
      and cancer antigens, might provide a clinical benefit. However, an expected side effect of&#xD;
      the presence of mature T cells is the potential occurrence of acute graft-versus-host disease&#xD;
      (aGVHD). BPX-501 contains genetically modified donor T cells that have an inducible safety&#xD;
      switch iCasp9 suicide gene. Evidence has emerged that escalating DLI has achieved higher&#xD;
      clinical response rate with lower GVHD occurrence. Optimization of DLI dose and schedule as&#xD;
      well as strategies of donor T-cell manipulation may lead to the consistent ability to&#xD;
      separate GVHD from GvL (graft-versus-leukemia) activity and improve the safety of DLI&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">January 2033</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BPX-501 Safety</measure>
    <time_frame>Month 24</time_frame>
    <description>To evaluate the safety of 2 stratified dose levels of BPX-501 T cell infusions based on patient-donor match in adult subjects with hematological malignancies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rimiducid Safety</measure>
    <time_frame>Month 24</time_frame>
    <description>evaluate the safety of the infusion of escalating doses of dimerizer drug rimiducid (AP1903) in subjects who develop acute GvHD after BPX-501 infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GvHD</measure>
    <time_frame>Month 24</time_frame>
    <description>Assess incidence and severity of acute and chronic GvHD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rimiducid Activity</measure>
    <time_frame>Month 24</time_frame>
    <description>Determine the effect of Rimiducid on mitigating GvHD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rimiducid Efficacy</measure>
    <time_frame>Month 24</time_frame>
    <description>Assess time to resolution of GvHD after administration of Rimiducid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Month 24</time_frame>
    <description>Measure overall survival, disease free survival and response rates after BPX-501 infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translational</measure>
    <time_frame>Month 24</time_frame>
    <description>Evaluate BPX-501 T cell function</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>BPX-501 and Rimiducid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive 3 cycles of BPX-501 T cell infusions at escalating dose levels (DL). DL1 on Day 0, DL2 on Days 30 and 60. The first dose of BPX-501 T cells will occur ≥30 days after hematopoietic stem cell transplant (HSCT).&#xD;
Two doses of Rimiducid ( 0.1 mg/kg and 0.4 mg/kg) will be investigated for the treatment of aGvHD after BPX-501 T cell infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BPX-501</intervention_name>
    <description>Biological: T cells transduced with CaspaCIDe suicide gene</description>
    <arm_group_label>BPX-501 and Rimiducid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rimiducid</intervention_name>
    <description>Rimiducid administered to treat GVHD</description>
    <arm_group_label>BPX-501 and Rimiducid</arm_group_label>
    <other_name>AP1903</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects aged &gt;18yrs and &lt; 65yrs&#xD;
&#xD;
          2. Clinical diagnosis of one of the following adult hematological malignancies&#xD;
&#xD;
               1. Leukemia&#xD;
&#xD;
               2. Myelodysplastic Syndromes&#xD;
&#xD;
               3. Lymphomas&#xD;
&#xD;
               4. Multiple myeloma&#xD;
&#xD;
               5. Other high-risk hematologic malignancies eligible for stem cell transplantation&#xD;
                  per institutional standard Life expectancy &gt;10 weeks&#xD;
&#xD;
          3. Evidence of recurrent disease that presents &gt; 100 days or minimal residual disease&#xD;
             (MRD) that presents &gt; 30 days after one of the following:&#xD;
&#xD;
               1. Matched related HSCT&#xD;
&#xD;
               2. Mismatched related HSCT&#xD;
&#xD;
          4. Signed patient informed consent;&#xD;
&#xD;
          5. A minimum genotypic identical match of 4/8 is required, as determined by high&#xD;
             resolution typing, at least one allele of each of the following genetic loci: HLA-A,&#xD;
             HLA-B, HLA-Cw, and HLA- DRB1&#xD;
&#xD;
          6. Performance status: Karnofsky score &gt; 50%&#xD;
&#xD;
          7. Subjects with adequate organ function as measured by:&#xD;
&#xD;
               1. Bone marrow:&#xD;
&#xD;
                    -  &gt; 25% donor T-cell chimerism&#xD;
&#xD;
                    -  ANC &gt;1 x 10E9/L&#xD;
&#xD;
               2. Cardiac: left ventricular ejection fraction at rest must be &gt;45%.&#xD;
&#xD;
               3. Hepatic: direct bilirubin ≤ 3 x upper limit of normal, or AST/ALT ≤ 5 x upper&#xD;
                  limit of normal&#xD;
&#xD;
               4. Renal: creatinine ≤ 2x of ULN for age&#xD;
&#xD;
               5. Pulmonary: FEV 1, FVC, DLCO (diffusion capacity) &gt; 50% predicted (corrected for&#xD;
                  hemoglobin)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. ≥ Grade II acute GVHD or chronic extensive GVHD due to a previous allograft at time of&#xD;
             screening;&#xD;
&#xD;
          2. Active CNS involvement by malignant cells;&#xD;
&#xD;
          3. Current uncontrolled bacterial, viral or fungal infection (currently taking medication&#xD;
             with evidence of progression of clinical symptoms or radiologic findings). The&#xD;
             principal investigator is the final arbiter of this criterion;&#xD;
&#xD;
          4. Positive HIV serology or viral RNA&#xD;
&#xD;
          5. Pregnancy (positive serum βHCG test) or breast-feeding;&#xD;
&#xD;
          6. Subjects of reproductive potential unwilling to use effective forms of birth control&#xD;
             or abstinence for a year after transplantation;&#xD;
&#xD;
          7. Bovine product allergy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bellicum Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Bellicum Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BMT Program at Northside Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>June 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2015</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adult leukemias and myelodysplasia</keyword>
  <keyword>Adult lymphomas</keyword>
  <keyword>Adult multiple myeloma</keyword>
  <keyword>allogeneic stem cell transplant</keyword>
  <keyword>donor lymphocyte infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

